$0.33 -0.00 (-1.35%) CTI BioPharma Corp - NASDAQ

Jul. 28, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.33
Trade Time: Jul 28 04:00 PM Eastern Daylight Time
Change: +-0.00 (-1.35%)
Prev Close: 0.33
Open: 0.34
Bid: 0.33
Ask: 0.33
  1. No results found.
  1. Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against CTI ...

    GuruFocus | Feb. 16, 2016 | 23:03PM EST
  2. CTI-Baxalta Drug Withdrawn, Removing Potential Incyte Rival

    IBD | Feb. 10, 2016 | 13:50PM EST
  3. Benzinga's Top Downgrades

    Benzinga | Feb. 10, 2016 | 09:20AM EST
  4. Mid-Afternoon Market Update: Crude Oil Down 3%; Biocryst Pharmaceuticals Shares Drop Following Announcement of Failed Avoralstat Trial Results

    Benzinga | Feb. 8, 2016 | 14:32PM EST
  5. Mid-Day Market Update: Dow Tumbles Over 350 Points; Apollo Education Shares Spike Higher

    Benzinga | Feb. 8, 2016 | 12:05PM EST
  6. Mid-Morning Market Update: Markets Open Lower; Hasbro Beats Q4 Estimates

    Benzinga | Feb. 8, 2016 | 09:53AM EST
  7. CTI BioPharma Announces FDA Places Partial Clinical Hold on Pacritinib IND

    Benzinga | Feb. 8, 2016 | 05:36AM EST
  8. CTI BioPharma, Baxalta Complete Submission of NDA for Pacritinib for Unmet Medical Need In Myelofibrosis

    Benzinga | Jan. 5, 2016 | 04:15AM EST
  9. CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    Benzinga | Dec. 14, 2015 | 04:08AM EST
  10. Analysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden

    Benzinga | Dec. 5, 2015 | 10:19AM EST
  11. Morning Market Gainers

    Benzinga | Nov. 23, 2015 | 09:44AM EST
  12. CTI BioPharma Initiates Rolling Submission of U.S. NDA for Pacritinib for Treatment of Patients with Myelofibrosis

    Benzinga | Nov. 23, 2015 | 04:10AM EST
  13. CTI BioPharma Announces Data Presentations at the 57th ASH Annual Meeting

    Benzinga | Nov. 6, 2015 | 04:19AM EST
  14. CTI BioPharma Prices Underwritten Public Offering of $50M of Convertible Preferred Stock

    Benzinga | Oct. 27, 2015 | 09:15AM EST
  15. CTI BioPharma, Fred Hutchinson Cancer Research Center Establish $1.5M Research Endowment Fund

    Benzinga | Oct. 1, 2015 | 04:29AM EST
Trading Center